Harvey Investment Co. LLC Acquires 1,745 Shares of Waters Corporation $WAT

Harvey Investment Co. LLC grew its holdings in Waters Corporation (NYSE:WAT) by 5.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 33,487 shares of the medical instruments supplier’s stock after acquiring an additional 1,745 shares during the period. Waters accounts for 1.1% of Harvey Investment Co. LLC’s portfolio, making the stock its 24th largest holding. Harvey Investment Co. LLC owned 0.06% of Waters worth $10,040,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. IFP Advisors Inc increased its stake in shares of Waters by 65.4% in the 2nd quarter. IFP Advisors Inc now owns 134 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 53 shares in the last quarter. CYBER HORNET ETFs LLC bought a new stake in Waters during the second quarter valued at about $53,000. MUFG Securities EMEA plc purchased a new stake in Waters in the second quarter worth about $61,000. Creative Financial Designs Inc. ADV raised its stake in shares of Waters by 533.3% in the second quarter. Creative Financial Designs Inc. ADV now owns 190 shares of the medical instruments supplier’s stock worth $66,000 after buying an additional 160 shares during the period. Finally, Steph & Co. purchased a new position in shares of Waters during the 2nd quarter valued at about $73,000. Hedge funds and other institutional investors own 94.01% of the company’s stock.

Waters Stock Performance

WAT opened at $381.97 on Monday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.08 and a current ratio of 1.53. The stock has a market capitalization of $22.75 billion, a price-to-earnings ratio of 35.11, a PEG ratio of 3.19 and a beta of 1.16. The company has a fifty day moving average of $381.61 and a 200 day moving average of $337.09. Waters Corporation has a fifty-two week low of $275.05 and a fifty-two week high of $423.56.

Waters (NYSE:WAT) last issued its quarterly earnings data on Thursday, May 19th. The medical instruments supplier reported $2.29 earnings per share for the quarter. Waters had a return on equity of 36.59% and a net margin of 20.89%.The firm had revenue of $608.55 million during the quarter. As a group, sell-side analysts forecast that Waters Corporation will post 12.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on WAT. JPMorgan Chase & Co. increased their target price on shares of Waters from $300.00 to $325.00 and gave the stock a “neutral” rating in a report on Thursday, October 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Waters in a research note on Wednesday, October 8th. Redburn Partners set a $390.00 price objective on shares of Waters in a research report on Wednesday, October 8th. William Blair started coverage on shares of Waters in a research note on Monday. They set an “outperform” rating on the stock. Finally, Wells Fargo & Company increased their price target on Waters from $385.00 to $415.00 and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $392.19.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.